Olivia D Lara1, Ying Wang2, Amma Asare3, Tao Xu4, Hua-Sheng Chiu5, Yuexin Liu2, Wei Hu1, Pavel Sumazin5, Shitanshu Uppal4, Lin Zhang6, J Alejandro Rauh-Hain1, Anil K Sood1,7. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Baylor College of Medicine, Houston, Texas. 4. Department of Gynecologic Oncology, University of Michigan, Ann Arbor, Michigan. 5. Texas Children's Cancer Center, Houston, Texas. 6. Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania. 7. Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Racial disparities in cancer outcomes are increasingly recognized, but comprehensive analyses, including molecular studies, are limited. The objective of the current study was to perform a pan-cancer clinical and epigenetic molecular analysis of outcomes in African American (AA) and European American (EA) patients. METHODS: Cross-platform analyses using cancer databases (the Surveillance, Epidemiology, and End Results program database and the National Cancer Data Base) and a molecular database (The Cancer Genome Ancestry Atlas) were performed to evaluate clinical and epigenetic molecular differences between AA and EA patients based on genetic ancestry. RESULTS: In the primary pan-cancer survival analysis using the Surveillance, Epidemiology, and End Results database (2,045,839 patients; 87.5% EA and 12.5% AA), AA patients had higher mortality rates for 28 of 42 cancer types analyzed (hazard ratio, >1.0). AAs continued to have higher mortality in 13 cancer types after adjustment for socioeconomic variables using the National Cancer Database (5,150,023 patients; 11.6% AA and 88.4% EA). Then, molecular features of 5,283 tumors were analyzed in patients who had genetic ancestry data available (87.2% EA and 12.8% AA). Genes were identified with altered DNA methylation along with increased microRNA expression levels unique to AA patients that are associated with cancer drug resistance. Increased miRNAs (miR-15a, miR-17, miR-130-3p, miR-181a) were noted in common among AAs with breast, kidney, thyroid, or prostate carcinomas. CONCLUSIONS: The current results identified epigenetic features in AA patients who have cancer that may contribute to higher mortality rates compared with EA patients who have cancer. Therefore, a focus on molecular signatures unique to AAs may identify actionable molecular abnormalities.
BACKGROUND: Racial disparities in cancer outcomes are increasingly recognized, but comprehensive analyses, including molecular studies, are limited. The objective of the current study was to perform a pan-cancer clinical and epigenetic molecular analysis of outcomes in African American (AA) and European American (EA) patients. METHODS: Cross-platform analyses using cancer databases (the Surveillance, Epidemiology, and End Results program database and the National Cancer Data Base) and a molecular database (The Cancer Genome Ancestry Atlas) were performed to evaluate clinical and epigenetic molecular differences between AA and EApatients based on genetic ancestry. RESULTS: In the primary pan-cancer survival analysis using the Surveillance, Epidemiology, and End Results database (2,045,839 patients; 87.5% EA and 12.5% AA), AA patients had higher mortality rates for 28 of 42 cancer types analyzed (hazard ratio, >1.0). AAs continued to have higher mortality in 13 cancer types after adjustment for socioeconomic variables using the National Cancer Database (5,150,023 patients; 11.6% AA and 88.4% EA). Then, molecular features of 5,283 tumors were analyzed in patients who had genetic ancestry data available (87.2% EA and 12.8% AA). Genes were identified with altered DNA methylation along with increased microRNA expression levels unique to AA patients that are associated with cancer drug resistance. Increased miRNAs (miR-15a, miR-17, miR-130-3p, miR-181a) were noted in common among AAs with breast, kidney, thyroid, or prostate carcinomas. CONCLUSIONS: The current results identified epigenetic features in AA patients who have cancer that may contribute to higher mortality rates compared with EApatients who have cancer. Therefore, a focus on molecular signatures unique to AAs may identify actionable molecular abnormalities.
Authors: Foluso O Ademuyiwa; Yu Tao; Jingqin Luo; Katherine Weilbaecher; Cynthia X Ma Journal: Breast Cancer Res Treat Date: 2016-12-03 Impact factor: 4.872
Authors: Jiao Yuan; Zhongyi Hu; Brandon A Mahal; Sihai D Zhao; Kevin H Kensler; Jingjiang Pi; Xiaowen Hu; Youyou Zhang; Yueying Wang; Junjie Jiang; Chunsheng Li; Xiaomin Zhong; Kathleen T Montone; Guoqiang Guan; Janos L Tanyi; Yi Fan; Xiaowei Xu; Mark A Morgan; Meixiao Long; Yuzhen Zhang; Rugang Zhang; Anil K Sood; Timothy R Rebbeck; Chi V Dang; Lin Zhang Journal: Cancer Cell Date: 2018-10-08 Impact factor: 31.743
Authors: Jeanne P Uyisenga; Ahmed Debit; Christophe Poulet; Pierre Frères; Aurélie Poncin; Jérôme Thiry; Leon Mutesa; Guy Jerusalem; Vincent Bours; Claire Josse Journal: Sci Rep Date: 2021-06-03 Impact factor: 4.379